SYMPOSIUM AGENDA
4TH International LFS Association Symposium

WEDNESDAY, APRIL 25
6:00-9:00PM
REGISTRATION AND WELCOME RECEPTION: GALLERY, PGCR, THE HOSPITAL FOR SICK CHILDREN, TORONTO, CANADA

THURSDAY, APRIL 26
8:00-9:00: REGISTRATION AND BREAKFAST: GALLERY, PGCR, THE HOSPITAL FOR SICK CHILDREN, TORONTO, CANADA, ROBERT SALTER AUDITORIUM, PETER GILGAN CENTRE FOR RESEARCH AND LEARNING
9:00-9:15: DR. DAVID MALKIN, HOSPITAL FOR SICK CHILDREN, AND LIFE CONSORTIUM CHAIR
9:15-9:25: DR. TREVOR YOUNG, DEAN, FACULTY OF MEDICINE, UNIVERSITY OF TORONTO
9:25-9:30: DR. MICHAEL APKON, PRESIDENT AND CEO, THE HOSPITAL FOR SICK CHILDREN, TORONTO, CANADA
9:30-9:35: DR. RONALD COHN, PEDIATRICIAN-IN-CHIEF, THE HOSPITAL FOR SICK CHILDREN, CHAIR, DEPARTMENT OF PEDIATRICS, UNIVERSITY OF TORONTO
9:40-9:45: JAMIE HIGGINS AND CAMERON BLOCK, ‘PATIENT PERSPECTIVES’
9:45-10:00: DR. ROBERT LUFKIN, MEDICAL DIRECTOR, LFSA/ JENN PERRY, PRESIDENT, LFSA
10:00-10:45: KEYNOTE ADDRESS: PROF. SIR DAVID LANE, A*STAR, SINGAPORE

10:45 -11:15: BREAK

SESSION 1: MODELING LI-FRAUMENI SYNDROME – I
11:15-11:35: DR. JOSHUA SCHIFFMAN, HUNTSMAN CANCER CENTER, SALT LAKE CITY, UT
Exploring elephant p53 (EP53) as a mechanism for cancer resistance
11:35-11:55: PROF. DAVID LANGENAU, MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA
Fishing for insights into LFS using p53-deficient zebrafish
11:55-12:15: DR. JASON BERMAN, DALHOUSE UNIVERSITY, HALIFAX, CANADA
Fishing for clues: preventing disease progression in cancer predisposition syndromes using zebrafish
12:15-12:35: DR. GERRY ZAMBETTI, ST. JUDE CHILDREN’S RESEARCH HOSPITAL, MEMPHIS, TN
The hypomorphic Brazilian mutant TP53-R337H and variable tumor susceptibility: identification of a genetic modifier
12:35-1:40: LUNCH

SESSION 2: MODELING LI-FRAUMENI SYNDROME – II
1:40-2:00: DR. ADAM SHLIEN, HOSPITAL FOR SICK CHILDREN, TORONTO, CANADA
Signatures and timing of mutations in sporadic and inherited childhood cancers
2:00-2:20: MR. BEN BREW, HOSPITAL FOR SICK CHILDREN, TORONTO, CANADA
Using methylation to predict early cancer onset in patients with Li-Fraumeni syndrome
2:20-2:40: PROF. DAVID THOMAS, SYDNEY, AUSTRALIA
Whole genome analysis of 1141 patients with sarcoma: Li-Fraumeni syndrome and beyond
2:40-3:00: DR. WENYI WANG, MD ANDERSON CANCER CENTER, HOUSTON, TX
Cancer risk assessment and penetration estimation for deleterious mutations in TP53 using a multi-centre consortium
3:00-3:30: BREAK

THURSDAY, APRIL 26 (continued)
3:30-3:50: PROF. GARETH BOND, OXFORD UNIVERSITY, UNITED KINGDOM
Common genetic variants in p53 pathway affect cancer risk in the general population and LFS families, but could benefit cancer management strategies
3:50-4:10: PROF. GIGI LOZANO, MD ANDERSON CANCER CENTER, HOUSTON, TX
Mutant p53 activities in tumor development
4:10-4:30: PROF. CAROL PRIVES, COLUMBIA UNIVERSITY, NEW YORK, NY
Are the opposite roles of wild-type and mutant p53 regulation of the mevalonate pathway relevant to treatment options for LFS patients?
4:45-6:00: CONCURRENT LFS FAMILY MEMBER WORKSHOPS
6:30: LFS FAMILY & FRIENDS “FUN IS OUR DNA” PUB NIGHT AT THE MONARCHS PUB, CHELSEA HOTEL & TORONTO BLUE JAYS VS. BOSTON RED SOX

FRIDAY, APRIL 27
7:30-8:30: BREAKFAST

SESSION 3: LI-FRAUMENI SYNDROME – THE HUMAN PHENOTYPE AND GENOTYPE – I
8:30-8:40: DR. LOUISE STRONG, MD ANDERSON CANCER CENTER, HOUSTON, TX
The evolving cancer risk in Li-Fraumeni syndrome
8:40-9:00: DR. KIM NICHOLS, ST. JUDE CHILDREN’S RESEARCH HOSPITAL, MEMPHIS, TN
Looking into the crystal ball: impact of germline TP53 status on presentation and prognosis for children with acute lymphoblastic leukemia
9:00-9:20: DR. CHRISTIAN KRATZ, UNIVERSITY OF HANNOVER, GERMANY
A new LFS/cancer predisposition registry based in Germany
9:20-9:40: PROF. LAURENCE BRUGIERES, GUSTAVE ROUSSY, FRANCE
Pediatric sarcomas associated with LFS: clinical characteristics, response to treatment, and outcomes
9:40-10:00: DR. MARIA ISABEL ACHATZ, NATIONAL CANCER INSTITUTE, BETHESDA, MD
How frequent is Li-Fraumeni Syndrome and pathogenic variants in the TP53 gene in the general population
10:00-10:30: BREAK

SESSION 4: LI-FRAUMENI SYNDROME – THE HUMAN PHENOTYPE AND GENOTYPE – II
10:30-10:50: DR. JUDY GARBER, DANA-FARBER CANCER INSTITUTE, BOSTON
Evolving phenotype of Li-Fraumeni Syndrome: data from panel testing
10:50-11:10: DR. PATRICIA PROLLA, PORTO ALLEGRE, BRAZIL
Mechanisms of cancer predisposition in R337H carriers: new insights
11:10-11:30: DR. SHARON PLON, HOUSTON, TX
Efforts to improve the molecular diagnosis of LFS in childhood cancer
11:30-11:50: DR. GARETH EVANS, MANCHESTER UNIVERSITY, UNITED KINGDOM
Germline TP53 mutations in the United Kingdom: Whole-Body MRI and other considerations
11:50-12:10: PROF. CHANG CHAN, RUTGERS UNIVERSITY, BRUNSWICK, NJ
Tumorigenesis and penetration in Li-Fraumeni syndrome
SESSION 7: METABOLISM AND IMMUNITY IN LI-FRAUMENI SYNDROME
10:20-10:40: DR. AYELET EREZ, WEIZMANN INSTITUTE OF SCIENCE, ISRAEL
Implications from cancer metabolism to immunity